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Abstract
Background: Acute myeloid leukemia (AML), an aggressive clonal disease, is genetically heterozygous. The prognostic role 
of  expression of  Breast Cancer Resistance Protein (BCRP) gene, which behaves as a multidrug transporter, in adult AML is 
ambiguous. 
Objective: The objective is to assess the level of  mRNA expression of  BCRP gene in newly diagnosed cytogenetically normal 
adult Egyptian AML patients; and to clarify its potential influence and association between therapeutic responsiveness and dis-
ease free survival.
Methods: The BCRP gene expression was evaluated by quantifying its mRNA using real time RT-PCR in fifty newly diagnosed 
cytogenetically normal adult AML patients and 20 healthy normal controls. The expression was evaluated in relation to clinical 
and prognostic factors, response to treatment and the survival rate. 
Results: BCRP mRNA was over expressed in adult AML patients compared to controls. This study showed a positive statistical 
correlation between BCRP gene expression and the percent of  CD34 expression. Statistical analysis did not reveal  any associa-
tion between BCRP expression level and chemotherapeutic responsiveness or disease free survival rate. 
Conclusion: The significance of  BCRP gene expression and its function in AML is very complicated, therefore more standard-
ized clinical studies are needed.
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Acute myeloid leukemia (AML), clonal malignant ag-
gressive hematological disease, caused by accumulating 
acquired genetic abnormalities in hematopoietic stem 
cells1. It includes diverse categories according to molec-
ular and other cytogenetic abnormalities2. Several prog-
nostic markers were described in AML, including genetic 
mutations, polymorphisms or over expression of  specific 
genes3. 
One of  these prognostic factors is the multidrug resis-
tance (MDR) phenotype confirmed by the presence of  
transmembrane transporter proteins in leukemic cells4.
The Breast Cancer Resistance Protein (BCRP), synony-
mously known as ATP-binding-cassette protein, is coded 
by a gene located on chromosome 4q22, it encodes a pro-
tein composed of  655-amino acids, when  over expressed 
it creates a drug resistance phenotype in tumor cell lines5. 
Such abnormal phenotype is due to the pump out of  a 
large spectrum of  chemicals, including chemotherapeutic 
drugs, outside the cells by the transport function of  this 
protein. So  it’s expression has a particular influence on 
cancer treatment6.
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The overexpression of  BCRP gene enables cancer cell 
lines to self-renew and differentiate, which are their main 
characteristic feature5. These cells play a crucial role in 
MDR, where their BCRP overexpression enable them to 
resist chemotherapy and survive after being exposed to 
chemotherapeutics. It is possible that by inhibiting BCRP, 
the cancer cells could be targeted and eradicated5,7.
A limited  number of  clinical prognostic studies dis-
cussed BCRP mRNA expression in AML, with different 
selection criteria and interpretation methodology8-13. The 
aim of  the current study is to assess the level of  mRNA 
expression of  BCRP gene by real time RT-PCR in 50 
newly diagnosed cytogenetically normal adult Egyptian 
AML patients, trying to clarify its potential influence and 
its association between the therapeutic responsiveness 
and disease free survival.
Subjects and methods
Study population
The present study was applied on 50 newly diagnosed 
cytogenetically normal adult AML patients. They were 
26(52%) males and 24(48 %). females The age of  the in-
cluded patients ranged from 18 to 71 years with a mean of  
41.2±15.9 years. Patients were selected over six months 
from National Cancer Institute, Cairo, Egypt. The Eth-
ical Committee of  National Cancer Institute approved 
the current research protocol. All procedures performed 
in the current study were in accordance with the World 
Medical Association Declaration of  Helsinki and its later 
amendments. Twenty age and sex-matched healthy unre-
lated blood donors participated in this study as a control 
group.
After collection of  written informed consent from all 
participants, patients were subjected to full clinical assess-
ment in addition to bone marrow examination. Immu-
nohistochemistry  staining and immuno-phenotyping was 
carried out to confirm the diagnosis and for  classification 
of  AML. Chromosomal karyotyping, molecular analysis 
with special emphasis on; t (8;21), inversion of  chromo-
some 16, Nucleophosmin (NPM) gene mutations and 
FMS-like tyrosine kinase 3 -internal tandem duplication 
(FLT3-ITD) were done. Patients diagnosed as promyelo-
cytic leukemia (M3), were not included in the study due to 
different therapeutic modalities and prognostic criteria. 
AML patients were followed up over the period of  induc-
tion chemotherapy and for twelve months.
BCRP m-RNA expression:
From cases and control samples, cellular RNA was ex-
tracted, then the complementary DNA was synthesized 
using QIAamp RNA blood Mini Kit, supplied by Qia-
gen, and High capacity cDNA Archive kit, provided by 
Applied Bio systems, respectively, the manufacture in-
structions were followed for each kit. Every PCR am-
plification reaction had a total volume of  25 μL which 
included: 1 μL of  the cDNA, 12.5 μLTaqMan universal 
PCR master mix (Applied Biosytems, Inc.), 1 μL of  each 
forward and reverse primers of  BCRP with the follow-
ing sequences;5'-CAGTACTTCAGCATTCCACGAT-3', 
and: 5'-GGCAGAAGTTTTGTCCCAAA-3'.  In addi-
tion to 0.5μL of  the probe of  Taqman with the sequence 
of  5'-FAM-CATTATGCTGCAAAGCCGTAAATC-
CA-TAMRA-3’. The Glyceraldehyde 3-phosphate dehy-
drogenase (GADPH) gene was selected to be the house-
keeping gene. The PCR reaction was programmed for; 10 
min heating at 95°C, followed by 40 cycles of; 15 s heating 
at 95°C for denaturation and 1min at 60 °C for annealing 
and elongation. Each PCR run included negative control 
tube without addition of  any cDNA template. The “com-
parative threshold method” (2 -ΔΔCT) was used to calcu-
late the relative expression level of  BCRP gene13.
 
Treatment protocol and response to therapy
The  AML patients were treated in accordance to the pro-
tocol of  the Department of  Medical Oncology, Kasr Al-
Ainy Faculty of  Medicine, CairoUniversity. Induction and 
consolidation were the two implemented phases of  ther-
apy. The remission was induced by 7-3 protocol, where 
fit patients (who were <60–65 years old, and selected fit 
patients up to age 75 years) received intensive therapy. 
Whereas less fit patients (who were70–75 years and older, 
or younger patients with significant co-morbidities) re-
ceived lower intensive therapy. To achieve this induction-
phase, a combination of  cytarabine and anthracycline or 
anthracenedione was recommended (cytarabine 100–200 
mg/m2 continuous IV infusion for 7 days, and for 3 days 
idarubicin 12 mg/m2/day, or daunorubicin 60–90 mg/
m2/day were added). All patients were assessed for risk 
of  relapse. Specific drug protocol, for consolidation ther-
apy, were recommended based on the risk of  relapse of  
the patient, high-dose cytarabine 3 g/m2 IV over 3 h ev-
ery 12 h on days 1, 3 and 5 for 4 cycle.
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After induction therapy, Complete remission(CR) was 
obtained when the patient had a cellular marrow with 
blast cells ≤5%, peripheral blood picture with a neutro-
phil count ≥1.5×103/ml, platelet count≥100×103/ml, 
and with no verification of  leukemia in other sites. The 
patient was stated to be primary resistant if  having cellu-




Data arrangement and analysis were done using Statistical 
Analysis Systems, SAS vs8.02. The graphs were done us-
ing Harvard Graphics, vs4.
The data were summarized according to their type, where 
mean and standard deviations (SD) or median and range 
were used for numeric data, while percentages were used 
for categorical data. Mann-Witney test was performed to 
compare numeric variables. The Chi-square test was ap-
plied to compare groups regarding the categorical data, 
while for small sample size Fisher’s exact test was used. 
The strength of  association between two numeric vari-
ables was calculated  using Spearman’s correlation coeffi-
cient, where values close to 1 or -1 mean a perfect posi-
tive or negative correlation, respectively.
The disease free survival (DSF) was estimated starting 
from the time of  remission to relapse or death or loss to 
follow and was evaluated by the Kaplan and Meier meth-
od, while the log rank test was used for comparison. Each 
P-value < 0.05 was considered to be significant.
Results
The main laboratory data of  AML patients were summa-
rized in table 1. AML patients were categorized into two 
groups according to the relative expression of  BCRP gene: 
34 AML patients (68%) were considered as a high expres-
sors, with relative expression level higher than that of  the 
controls. Sixteen AML patients (32%) were considered 
as a low expressors, with relative expression level within 
the range of  the normal controls. There was no statistical 
significant difference between the two patients’category 
regarding their clinical and laboratory data.






Sex Male 26/50 (52%) 
Female 24/50(48%) 
Hepatomegaly 12/50 (24%) 
Splenomegaly 12/50(24%) 
Lymphadenopathy 4/50(8%) 



































M1 13/50( 26%) 
M2 23/50(46%) 
M4 13/50( 26%) 
Molecular genetics 
  
t (8; 21) 4/50 (8%) 
inv (16) 1/50(2%) 
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A significant statistical difference  was detected between 
the BCRP mRNA expression level and the percentage of  
blast cells expressing CD34 (p= 0.016, r= 0.330) in AML 
patients. Otherwise there was no statistical significant cor-
relation could be found between BCRP gene expression 
and other clinical nor laboratory data of  AML patients 
including the distribution among different FAB subtypes.
After induction chemotherapy, Complete remission was 
achieved by 24 / 50 (48%) of  AML patients. Among 
these cases, 15/24(62.5%) were high expressors and 
9/24(37.5%) were low expressors. Twenty-six patients 
(52%) failed to achieve CR (12 patients showed resistance 
to induction treatment and 14 patients died during the 
course of  induction). No statistical significant differ-
ence could be detected between high and low expressors 
groups according to the response of  induction chemo-
therapy (Table 2). 
Table (2): Correlation of response rate with ABCG2 gene expression in 50 AML cases 
 
  High  BCRP m-RNA 
expression  






CR** 24 AML 
Patients 
15/24(62.5%) 9/24(37.5%)   
0.547 
Failed to achieve 
CR( resistance 




*P-values < 0.05 were considered significant. 
** CR; complete remission. 
  
Follow up of  AML patients for twelve months revealed 
that 18/24 (75%) patients who achieved CR after induc-
tion chemotherapy had a disease free survival(DFS)during 
the follow up period. Ten of  them were high BCRP ex-
pressors, while eight were low BCRP expressors. Six pa-
tients failed to achieve 6 months DFS, five of  them were 
high BCRP expressors and one patient was low BCRP 
m-RNA expressor. There was no statistically significant 
difference noticed between high and low BCRP expres-
sors regarding their DFS rate (Figure 1).
 
 
Figure (1): Kaplan Meier curve showing disease free survival in AML cases. 
Discussion
Several factors affect the prognosis of  adult AML, such 
as the age of  the patient, the strength of  post remission 
therapy, beside the biologic characteristics of  the disease. 
Karyotyping at the time of  diagnosis, the existence of  
transmembrane transporter proteins which grant mul-
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tidrug resistance. The over-expression or the mutations 
affecting particular genes are also included in the factors 
affecting the disease outcome4.
The present work revealed that BCRP mRNA transcript 
was not overexpressed in the peripheral blood of  normal 
healthy donors. Abbott et al.,8 found low levels of  BCRP 
mRNA expression in normal samples, whether peripher-
al blood or bone marrow, which reflected the restricted 
BCRP expression to the rare repopulating hematopoietic 
stem cells15.
We chose the cutoff  of  expression level to be the highest 
reading of  BCRP mRNA expression among the controls. 
Our results were in harmony with Abbott et al.,8 who 
classified 40 AML studies samples according the BCRP 
expression level into 3 levels: low expression level (lower 
than that of  normal PB and BM), intermediate level of  
expression (greater than normal PB and BM but lower 
or equal to MDR cells clone 3.3), and high expression 
level (greater than MDR clone 3.3). Nasilowska-Adamska 
et al.,13 on the other hand, chose the median of  BCRP 
mRNA expression level, in univariate analysis, as the cut-
off  for his results. 
Of  the 50 adult AML cases examined, 34 patients (68%) 
were high BCRP expressors.  Similarly the majority of  
adult AML samples showed over expression of  BCRP 
mRNA in comparison to normal controls in   Abbott et 
al.,8 study, but this was lower than MDR cell lines. This 
finding can be explained by either the homogenous ex-
pression of  BCRP by all leukemic cells, or that BCRP 
expression could be heterogeneous and restricted to a 
subpopulation of  leukemic cells.  Flow cytometry study 
of  BCRP protein expression levels in adult AML found 
that the later scenario was more likely8,9. 
In the current study, there was no statistically significant 
difference between AML patients with high BCRP ex-
pressors and low expressors regarding their clinical and 
laboratory data. Similarly,previous clinical studies on 
AML patients could not find an association between 
BCRP m-RNA expression and AML patient characteris-
tics such as age , hemoglobin and total leucocytic count, 
nor among different FAB subtypes7,9,10,13.
During the study of  the possible association between 
BCRP expression and other prognostic markers, a signif-
icant correlation between the BCRP mRNA expression 
level and the percentage of  CD34 expression on leuke-
mic blasts was found. Otherwise there was no statistically 
significant correlation between BCRP gene expression 
and other clinical nor laboratory data of  AML patients. 
This was in agreement with the results reported in van 
den Heuvel-Eibrink et al., study12 who found a significant 
positive association between CD34 expression and BCRP 
gene expression. Abbott et al.,8 and Suvannasankha et al,9 
could not find an association between and BCRP gene 
expression and other clinical nor other laboratory data, 
even the CD34 and or /CD33 expressing AML sub-pop-
ulation. In Nasilowska-Adamska  et al .,study13 the ex-
pression of  BCRP mRNA in blast cells, which were posi-
tive for CD34, was of  a marginal significance .
Controversy about the expression of  BCRP mRNA in 
human pluripotent stem cells has been encountered, 
where Zeng et al.,16 reported that these cells were less 
resistant to certain cytotoxic chemicals due to BCRP ex-
pression. However, with more sensitive techniques Sark-
adi et al.,17 suggested that BCRP expression was at a rela-
tively high level in the human undifferentiated stem cells, 
which highlights its role in protecting this valuable stem 
cells from the damage caused by toxins, drugs or hypoxia.
The present work did not conceal a significant difference 
in BCRP mRNA expression as regard the early treatment 
response nor to the respect of  DFS of  the patients. Our 
results were consistent with Abbott et al.,8 and Suvanna-
sankhaet al.,9.
Furthermore, Uggla et al.,11 could not find a difference 
between treatment AML responders and non-responders 
patients as regards BCRP expression, but in the group of  
responding patients, those with uppermost BCRP mRNA 
expression showed significantly shorter overall survival.
On the contrary, the study of  Nasilowska-Adamska  et 
al.,13 found that, in a univariate analysis, the BCRP expres-
sion  was associated with higher early relapse rate and 
significantly influenced the disease free survival in AML. 
Also van den Heuvel-Eibrink et al.,12 reported that BCRP 
expression was frequently up regulated in patients with 
relapsed AML. In addition, high BCRP expression lev-
el in AML patients has been associated with a relapsed 
or refractory state, lower complete response and short-
er survival rates10,18. Damiani et al.,7,19 reported the same 
finding and stated that there was an up regulation in 
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BCRP protein at relapsed AML samples when compared 
to newly diagnosed ones and it can identify AML patients 
with poor outcome even after stem cell transplantation.
As the biology of  BCRP gene expression and its role in 
AML is  much more complicated than in cell line mod-
els8, our study could not find a clear association between 
BCRP overexpression in adult AML cases and its possi-
ble contribution as a molecular predictor to the response 
of  therapy. This could be attributed to the discordance 
between BCRP mRNA overexpression and subsequent 
translation into a functioning trans-membrane protein 
in a malignant and genetically complex disease such as 
AML20. Furthermore underlying genetic polymorphisms 
of  the BCRP gene, as a part of  the genetic heterogeneity 
in AML, could affect the expression levels with subse-
quent influence on the disease progression6 multiple ge-
netic, together with heterogeneous functional proteins, 
interactions need to be clarified in AML.
In  order to better understand the clinical role of  BCRP 
in AML, we recommend the estimation of  the BCRP ex-
pression in a bigger cohort of  AML patients, study genet-
ic polymorphisms that could affect the expression levels, 
standardize several factors including patient selection, 
used chemotherapeutic drugs and development of  con-
sensus recommendations for BCRP detection. Moreover, 
longer follow up period will clarify the possible influence 
of   BCRP expression  on DFS and overall survival of  the 
disease.
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